Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)Business Wire • 06/07/23
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer's Disease (AD)Business Wire • 06/05/23
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer's Disease (AD) at the LD Micro Conference on June 7, 2023Business Wire • 05/22/23
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep goingZacks Investment Research • 05/16/23
Coya Therapeutics' COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer's DiseaseBusiness Wire • 05/16/23
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial ResultsBusiness Wire • 05/10/23
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ETBusiness Wire • 05/09/23
Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune DiseasesSeeking Alpha • 05/08/23
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?Accesswire • 04/14/23
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023Business Wire • 03/31/23
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial ResultsBusiness Wire • 03/29/23
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business OfficerBusiness Wire • 03/27/23
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ETBusiness Wire • 03/23/23
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ETBusiness Wire • 03/21/23
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)Business Wire • 03/21/23
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative DiseasesBusiness Wire • 03/20/23
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ETBusiness Wire • 03/09/23
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.Business Wire • 02/27/23
Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya's Low-Dose Interleukin 2 (IL-2) Product CandidateBusiness Wire • 02/15/23
Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023Business Wire • 02/02/23
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer's Disease (AD)Business Wire • 01/26/23
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public OfferingBusiness Wire • 01/03/23
Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public OfferingBusiness Wire • 12/29/22
